Homologous Recombination Deficiency Detection Algorithms: A Systematic Review

LR Mark, SK Terp, HB Krarup, M Thomassen… - Cancers, 2023 - mdpi.com
Simple Summary Homologous recombination deficiency (HRD) originates from genomic
mutations or alterations in the homologous recombination repair pathway. Various …

[HTML][HTML] Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian …

M Zhou, Y Sun, Y Sun, W Xu, Z Zhang, H Zhao… - Oncotarget, 2016 - ncbi.nlm.nih.gov
There is growing evidence of dysregulated long non-coding RNAs (lncRNAs) serving as
potential biomarkers for cancer prognosis. However, systematic efforts of searching for an …

Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a …

J Sun, C Yan, D Xu, Z Zhang, K Li, X Li, M Zhou… - British Journal of …, 2022 - nature.com
Background Immunotherapy has revolutionised the field of cancer therapy and immunology,
but has demonstrated limited therapeutic efficacy in high-grade serous ovarian cancer …

The RECAP test rapidly and reliably identifies homologous recombination-deficient ovarian carcinomas

LM van Wijk, S Vermeulen, M Meijers, MF van Diest… - Cancers, 2020 - mdpi.com
Simple Summary The sensitivity to PARP inhibitors (PARPi) is related to tumor-specific
defects in homologous recombination (HR) and extends beyond BRCA1/2-related …

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

A Ewing, A Meynert, M Churchman, GR Grimes… - Clinical Cancer …, 2021 - AACR
Purpose: The abundance and effects of structural variation at BRCA1/2 in tumors are not
well understood. In particular, the impact of these events on homologous recombination …

Multi-omics deep-learning prediction of homologous recombination deficiency-like phenotype improved risk stratification and guided therapeutic decisions in …

Y Zhang, C Yan, Z Yang, M Zhou… - IEEE journal of …, 2023 - ieeexplore.ieee.org
Homologous recombination deficiency (HRD) is a well-recognized important biomarker in
determining the clinical benefits of platinum-based chemotherapy and PARP inhibitor …

[HTML][HTML] Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2

L Guo, Y Peng, Y Meng, Y Liu, S Yang, H Jin, Q Li - Oncotarget, 2017 - ncbi.nlm.nih.gov
Emerging evidence shows that dysregulated expression of microRNAs (miRNAs) and long
non-coding RNAs (lncRNAs) were closely linked with disease progression, including …

[PDF][PDF] Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package

S Pirrotta, L Masatti, A Bortolato, A Corrà… - NAR Genomics and …, 2024 - academic.oup.com
Understanding cancer mechanisms, defining subtypes, predicting prognosis and assessing
therapy efficacy are crucial aspects of cancer research. Gene-expression signatures derived …

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum …

J Sun, S Bao, D Xu, Y Zhang, J Su, J Liu, D Hao… - Cell death & …, 2019 - nature.com
Heterogeneity in chemotherapeutic response is directly associated with prognosis and
disease recurrence in patients with ovarian cancer (OvCa). Despite the significant clinical …

The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents

T Wang, G Wang, X Zhang, D Wu, L Yang, G Wang… - Scientific reports, 2017 - nature.com
Abstract miRNAs, a class of short but stable noncoding RNA molecules, have been revealed
to play important roles in the DNA damage response (DDR). However, their functions in …